Be the first to know with Philippe Sans: bioMerieux North America's President & CEO - Expert Opinion

Medical Laboratory Observer, March, 2003 by Celia Stevens

Celia Stevens: In your view, what are the key trends that will drive the future of the clinical diagnostics industry?

Philippe Sans: Diagnostic laboratories are under constant pressure to reduce costs and improve the turnaround time of test results while, many times, working with inadequate staffing. The challenge is for companies like bioMerieux to come up with solutions that enable laboratories to meet these demands. It is up to us to come up with economic solutions that reduce costs and improve patient outcomes for the healthcare system.

In this day and age, usable, timely information is key to the success of any operation, and laboratory diagnostics should be no different. I believe the laboratory has a wealth of information which the hospital may be underutilizing. This opens up a whole new area where the lab can demonstrate to the hospital how much more value its information can be to the overall patient care and economic picture.

Stevens: Nucleic acid diagnostics is one of your company's four major product lines. What impact will genomics and proteomics have on your future product offerings?

Sans: We are seeing a definite trend in terms of greater acceptance of analyte-specific reagents for esoterics in university hospitals, due to the need for rapid, sensitive results that can affect patient care decisions.

Our future product offerings depend on the adoption of molecular testing, and that will depend upon the cost/benefit ratios and ease-of-use features (real time, multiplex capability and sample preparation). If molecular testing allows laboratories to provide information that enables physicians to make management decisions during their shifts, the outlook can be very good.

bioMerieux has solutions for customers who want easy-to-use molecular systems with quick turnarounds. One example would be our NucliSens EasyQ system, which provides real-time detection using nucleic acid sequence-based amplification (NASBA) technology with molecular beacons for the identification or detection of infectious diseases and viral agents.

Another key example is the VIDAS probe amplification system, which will be launched this year. This dual platform system will offer fully automated amplification and detection by using TMA or Transcription Mediated Amplification. This will allow VIDAS users to utilize probe technology simply by adding an Amp station. This system is very easy to use; our first test launched will be chlamydia, with a planned menu expansion to include tuberculosis and gonorrhea, just to name a few. The tests will be both quantitative and qualitative.

Stevens: The history of your company is marked by significant acquisitions, the most recent being your acquisition of Organon Teknika's diagnostics division in July 2001. How has the integration proceeded?

Sans: We closed the transaction on June 29, 2001, and completed most of the integration by Dec. 31, 2001. We moved our U.s. headquarters from St. Louis, MO, to Organon Teknika's location in Durham, NC. The combined management team equally includes executives from both companies. The integration was made easier because both companies have European parent companies and similar corporate cultures.

We are proud of our new customer service organization. We have made a significant investment to improve our customer care. We merged two excellent customer service organizations, and as a result, we are building a world-class team.

All in all, this past year we grew U.S. revenue by double digits to about $250 million, exceeding our forecasts. By all measures, the integration has been a success.

Stevens: The fit between the microbiology line of Organon Teknika and bioMdrieux made a lot of sense. What is the future of the coagulation line?

Sans: The future for the coagulation product line has never been better. We now have key contracts with Fisher, Allegiance and Premier. Coupled with our patented "Waveform Analysis" technology that provides more information from routine PT and APTT assays than just clot time alone, we have every reason to be very optimistic about our coagulation business. This patented technology is particularly exciting, as the first clinical application is identification of an abnormal APTT waveform pattern that has been shown to be an early indicator of sepsis. Once again, a perfect fit for the bioMerieux focus on improving the diagnosis and management of infectious diseases.

Stevens: What impact will the threat of bioterrorism have on clinical microbiology products of the future?

Sans: That is a very good question. In the long term, I believe you will see a movement towards field-based testing instruments. In other words, I mean hand-held, point-of-care testing that is easy to use and gives immediate results, but has a very narrow purpose. In the short term, however, many of the tests will require patient specimens to be sent to a laboratory for analysis. I believe you will see additional appreciation for current systems, as well as expanded menus and added flexibility. During the anthrax scare, our automated BacT/ALERT3D played a major role in the initial detection of the anthrax cases, as the primary diagnostic test was blood culture.